The initial interest in brain CD2AP was sparked by the identification of genetic variants in the non-coding and coding regions of CD2AP in patients with Alzheimer’s disease (AD) via Genome-Wide Association Studies (GWAS). This evidence concerns the gene CD2AP and early-onset autosomal dominant Alzheimer disease.